C E Vitelli, L Fortunato, F Crenca, A Di Nardo, G Zarrelli, M Farina, S Bianca
{"title":"[Locally advanced and recurrent pelvic colorectal carcinoma: results of aggressive surgical treatment].","authors":"C E Vitelli, L Fortunato, F Crenca, A Di Nardo, G Zarrelli, M Farina, S Bianca","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Pelvic exenteration has been described as a formidable procedure in cases of advanced or recurrent pelvic cancers for a variety of primary tumors, including colorectal, gynaecologic and urologic. We report our 14-year experience in a community hospital with 37 cases who underwent pelvic exenteration for recurrent (n = 15) or locally advanced (n = 22) colorectal cancers. At a median follow-up of 36 months, the median survival was 24 and 36 months, respectively, and the 5-year actuarial survival was 18% and 44%.</p>","PeriodicalId":84869,"journal":{"name":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","volume":"4 3","pages":"S4"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Pelvic exenteration has been described as a formidable procedure in cases of advanced or recurrent pelvic cancers for a variety of primary tumors, including colorectal, gynaecologic and urologic. We report our 14-year experience in a community hospital with 37 cases who underwent pelvic exenteration for recurrent (n = 15) or locally advanced (n = 22) colorectal cancers. At a median follow-up of 36 months, the median survival was 24 and 36 months, respectively, and the 5-year actuarial survival was 18% and 44%.